 |
11 Diseases |  |
38 Trials |
|
38 Trials |  |
2772 News |  |
| «12...2728293031323334353637...3839» |
- Tremfya (guselkumab) / J&J, Cosentyx (secukinumab) / Novartis
[VIRTUAL] Differences in clinically relevant response types underlying the superior efficacy of guselkumab over secukinumab in psoriasis: results from a heatmap analysis of the ECLIPSE study () - Oct 20, 2020 - Abstract #EADV2020EADV_2631;
- Tremfya (guselkumab) / J&J
[VIRTUAL] Effects of Guselkumab, a Monoclonal Antibody that Specifically Binds to the p19-Subunit of Interleukin-23; on Dactylitis and Enthesitis in Patients with Active Psoriatic Arthritis: Pooled Results Through Week 24 from Two Phase 3 Studies () - Oct 20, 2020 - Abstract #EADV2020EADV_2629;
- Tremfya (guselkumab) / J&J
[VIRTUAL] Real-world effectiveness and safety of Guselkumab for the treatment of Psoriasis: a 6-month Analysis in a Series of Psoriatic Patients () - Oct 20, 2020 - Abstract #EADV2020EADV_1762;
- Tremfya (guselkumab) / J&J
[VIRTUAL] Guselkumab for Psoriatic Arthritis: Results from a Network Meta-Analysis () - Oct 20, 2020 - Abstract #EADV2020EADV_1739;
- [VIRTUAL] Excellent Response to Treatment in Hidradenitis Suppurativa Patient Treated with Guselkumab () - Oct 17, 2020 - Abstract #SHSA2020SHSA_87;
Recognize the importance of patient quality of life when deciding clinical management. Takeaway Message: Guselkumab may be a promising treatment option for the clinical management of HS patients who have failed prior intervention, including multiple biologic agents.
- ||| Humira (adalimumab) / Eisai, AbbVie, Tremfya (guselkumab) / J&J
Check out my commentaries on emerging #psoriasis data. I cover loss aversion in decision making, new mtx guidelines, new signs of systemic inflammation, deltas in pt and genetic outcomes in PASI 100 responders on #adalimumab vs. #guselkumab. @AADmember https://t.co/mwIceFQlsI (Twitter) - Oct 16, 2020
- || Humira (adalimumab) / Eisai, AbbVie, Tremfya (guselkumab) / J&J
Clinical, Journal: Guselkumab improves work productivity in patients with moderate-to-severe psoriasis with or without depression and anxiety: results from the VOYAGE 2 comparator study versus adalimumab. (Pubmed Central) - Oct 16, 2020
Improvements were consistent in patients with and without depression/anxiety. Psoriasis patients treated with guselkumab had significantly better improvements in absenteeism and presenteeism compared with those treated with adalimumab, regardless of depression/anxiety status.
- |||| Clinical: @JosephMerolaMD Hi I'm a psoriatic arthritis patient. It's nice to see an approachable looking rheumatologist on Twitter! Will read some of your research. Recently started Tremfya after Taltz, Simponi, Humira, and Enbrel. Fingers crossed, I seem to be doing well for now! (Twitter) - Oct 14, 2020
- ||||| Tremfya (guselkumab) / J&J
Clinical, Video: VIDEO: Guselkumab produces clinical, endoscopic response in Crohn’s https://t.co/DDXoZ04GrE @HealioGastro #UEGWeek2020 Dr Sandborn discusses results of this anti-IL-23--signif better than PBO at wk 12 for clin remission and endoscopic improvement--numerically better than UST (Twitter) - Oct 14, 2020
- | Tremfya (guselkumab) / J&J
If you swapped Tremfya for Zytiga, you wouldn't have been far off .... at least for the first 68 minutes of a 75 minute call. (Twitter) - Oct 13, 2020
- |||| Tremfya (guselkumab) / J&J
Encouraging data on guselkumab (anti-IL23) induction. A notch better than Uste, but not overwhelmingly better. IV dose appears to have flat dose/response. #IBD #UEGweek (Twitter) - Oct 12, 2020
- Tremfya (guselkumab) / J&J
[VIRTUAL] Efficacy of Guselkumab, a Monoclonal Antibody That Specifically Binds to the p19 Subunit of IL-23, on Axial-Related Endpoints in Patients with Active PsA with Imaging-Confirmed Sacroiliitis: Week-52 Results from Two Phase 3, Randomized, Double-blind, Placebo-controlled Studies (Feed 12) - Oct 8, 2020 - Abstract #ACRARHP2020ACR_ARHP_2696;
Psoriasis patients treated with guselkumab had significantly better improvements in absenteeism and presenteeism compared with those treated with adalimumab, regardless of depression/anxiety status. Improvements in axial symptoms were maintained through week 52 in GUS-treated pts with active PsA who had imaging-confirmed sacroiliitis
- Tremfya (guselkumab) / J&J
[VIRTUAL] Guselkumab Provides Domain-Specific and Comprehensive Efficacy as Assessed Using Composite Endpoints in Patients with Active Psoriatic Arthritis () - Oct 8, 2020 - Abstract #ACRARHP2020ACR_ARHP_2013;
Regardless of composite index employed or study population assessed, GUS 100 mg Q4W and Q8W provided robust benefits to patients with active PsA across multiple domains, indicating that GUS may offer a novel mechanism by which to treat the diverse manifestations of PsA. Excluding CRP from the DAPSA did not alter the instrument’s ability to discern treatment effect
- Tremfya (guselkumab) / J&J
[VIRTUAL] Guselkumab, an IL-23 Inhibitor That Specifically Binds to the IL23p19-Subunit, for Active Psoriatic Arthritis: One Year Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Patients Who Were Biologic-Naïve or TNFα Inhibitor-Experienced () - Oct 8, 2020 - Abstract #ACRARHP2020ACR_ARHP_2008;
In pts continuing in the study, improvements in skin symptoms, dactylitis, enthesitis, physical function, and quality of life were also maintained through 1 year. GUS 100 mg Q4W and Q8W were safe and well-tolerated through study completion and consistent with GUS safety in PsO.1 Reference: 1.
- Tremfya (guselkumab) / J&J
[VIRTUAL] Guselkumab Efficacy in Adult Patients with Active Psoriatic Arthritis by Baseline Demographic and Disease Characteristics: Pooled Results of Two Phase 3, Randomized, Placebo-Controlled Studies () - Oct 8, 2020 - Abstract #ACRARHP2020ACR_ARHP_1531;
GUS effects on joint (ACR50) and skin (Investigator’s Global Assessment [IGA=0/1 + ≥2-grade reduction from W0] in pts with ≥3% body surface area [BSA] psoriasis and IGA ≥2 at W0) responses were evaluated by pt sex, age, body weight, BMI, PsA duration, tender/swollen joint counts (ACR50 only), % BSA (IGA 0/1 only), CRP, and non-biologic (nb) DMARD/methotrexate (MTX) use at W0. The benefits of guselkumab 100 mg Q4W and Q8W in substantially improving signs and symptoms of active PsA appeared to be consistent irrespective of the baseline characteristics assessed
- Tremfya (guselkumab) / J&J
[VIRTUAL] Effects of Guselkumab, a Monoclonal Antibody That Specifically Binds to the p19-Subunit of Interleukin-23, on Dactylitis and Enthesitis in Patients with Active Psoriatic Arthritis: Pooled Results Through Week 24 from Two Phase 3 Studies () - Oct 8, 2020 - Abstract #ACRARHP2020ACR_ARHP_1518;
Resolution of dactylitis or enthesitis was significantly associated with clinically meaningful improvements in PsA joint & skin symptoms. Improved dactylitis scores correlated with improved skin symptoms and mental health; improved LEI scores correlated with improved physical function
- Humira (adalimumab) / Eisai, AbbVie, Tremfya (guselkumab) / J&J
[VIRTUAL] Four-Year Efficacy and Safety of Guselkumab in Psoriasis Patients with and Without Psoriatic Arthritis: A Pooled Analysis from VOYAGE 1 and VOYAGE 2 () - Oct 8, 2020 - Abstract #ACRARHP2020ACR_ARHP_1514;
1829 patients were randomized to GUS 100 mg at Weeks 0, 4, and 12, then every 8 weeks (q8wk); PBO at Weeks 0, 4, and 12, GUS at Weeks 16 and 20 then q8wk; or adalimumab (ADA) 80 mg at Week 0, 40 mg at Week 1, then 40 mg q2wk until Week 47 (VOYAGE 1) or Week 23 (VOYAGE 2). Among GUS-treated patients with moderate-to-severe PsO with and without self-reported PsA at baseline, stable, durable, and high levels of skin responses, as well as comparable safety outcomes, through 4 years were observed.
- Tremfya (guselkumab) / J&J
[VIRTUAL] Guselkumab Efficacy and Safety in TNF-Inhibitor-Experienced and TNF-Inhibitor-Naïve Patients with Active PsA: 1-Year Results of a Phase 3, Randomized, Controlled Study () - Oct 8, 2020 - Abstract #ACRARHP2020ACR_ARHP_1511;
Through 1 year, GUS 100 mg Q4W and Q8W provided robust and sustained improvements in joint symptoms and physical function in both TNFi-naïve and TNFi-experienced pts with active PsA. Meaningful improvements in skin psoriasis and composite disease state were observed, and GUS appeared to be well tolerated in PsA pts, regardless of prior TNFi status
- Tremfya (guselkumab) / J&J
[VIRTUAL] Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19-Subunit of Interleukin-23, Through Week 52 of a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naïve Patients with Active Psoriatic Arthritis (Feed 10) - Oct 8, 2020 - Abstract #ACRARHP2020ACR_ARHP_1064;
In biologic-naïve pts with active PsA, GUS elicited sustained improvements in joint & skin symptoms; inhibition of radiographic progression & improvements in physical function, quality of life & composite indices through W52. GUS safety in PsA was similar at W241 & W52 and consistent with GUS safety in psoriasis.
- Tremfya (guselkumab) / J&J
[VIRTUAL] Guselkumab-Treated Patients Achieved Clinically Meaningful Improvement in Systemic Symptoms as Measured with PROMIS Instrument: Results from Phase-3 Psoriatic Arthritis Trial DISCOVER 1 () - Oct 8, 2020 - Abstract #ACRARHP2020ACR_ARHP_959;
P3
GUS safety in PsA was similar at W241 & W52 and consistent with GUS safety in psoriasis. Active PsA patients treated with GUS achieved clinically meaningful reduction in symptoms and improvement in physical function and social participation vs PBO at W24 Reference: http://www.healthmeasures.net/score-and-interpret/interpret-scores/meaningful-change/165-meaningful-change
- Stelara (ustekinumab) / J&J, Tremfya (guselkumab) / J&J
[VIRTUAL] Guselkumab Induces Sustained Reduction in Acute Phase Proteins and Th17 Effector Cytokines in Active Psoriatic Arthritis in Two Phase-3 Clinical Trials (DISCOVER-1 and DISCOVER-2) () - Oct 8, 2020 - Abstract #ACRARHP2020ACR_ARHP_956;
Comprising a strong pharmacodynamic effect, GUS reduced serum protein levels of acute phase & Th17-effector cytokines (whose elevations at baseline were associated with PsA disease characteristics) & achieved comparable levels to those in healthy controls. In PsA pts, reductions of IL-17A & IL-17F by GUS were of greater magnitude than those by UST
- Tremfya (guselkumab) / J&J
[VIRTUAL] Patients with Psoriatic Arthritis Treated with Guselkumab Achieved Psoriasis-Related Symptom-Free State and Had No Skin Condition Impact on Their Health Related Quality of Life () - Oct 8, 2020 - Abstract #ACRARHP2020ACR_ARHP_951;
For DISCOVER-2, adults with active PsA (≥5 swollen + ≥5 tender joints; CRP ≥0.6 mg/dL) despite standard therapies (eg, non-biologic DMARDs, apremilast, or NSAIDs) were eligible. The majority of GUS-treated patients with PsA achieved skin-related symptom-free and no impact of skin condition on their HRQOL.
- Tremfya (guselkumab) / J&J
[VIRTUAL] Collagen Turnover Markers Are Associated with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase-3 Clinical Trial () - Oct 8, 2020 - Abstract #ACRARHP2020ACR_ARHP_944;
Importantly, C1M serves as a biomarker that tracks with joint response. We observed a greater reduction in C1M in ACR responders compared to non-responders, providing insight into how GUS may be working to protect from degradation of bone in PsA
- Tremfya (guselkumab) / J&J
[VIRTUAL] Pooled Safety Results from Two Phase-3 Trials of Guselkumab in Patients with Psoriatic Arthritis Through 1 Year () - Oct 8, 2020 - Abstract #ACRARHP2020ACR_ARHP_938;
There were no meaningful differences between incidences of AEs reported in the q8w and q4w groups. The safety profile of GUS in PsA patients is generally comparable with the previously established safety profile of GUS
- Tremfya (guselkumab) / J&J
[VIRTUAL] In Two Phase-3 Trials, Guselkumab Reduced Fatigue over 52 Weeks in Patients with Psoriatic Arthritis and Demonstrated Independent Treatment Effects on Fatigue After Adjustment for Clinical Response (ACR20) () - Oct 8, 2020 - Abstract #ACRARHP2020ACR_ARHP_936;
In 2 phase-3 trials, GUS treatment improved fatigue when compared to PBO during PBO-controlled periods and maintained improvements through 1 year of active treatment. Substantial proportions of those effects were independent of the effects on ACR 20, especially for the q4W dosing group
- Tremfya (guselkumab) / J&J
[VIRTUAL] Comparative Efficacy of Guselkumab in Patients with Psoriatic Arthritis: Results from Systematic Literature Review and Network Meta-Analysis () - Oct 8, 2020 - Abstract #ACRARHP2020ACR_ARHP_922;
GUS provides joint arthritis efficacy (ACR responses and modified vdH-S score), physical function (HAQ-DI score), and safety outcomes that is comparable to most targeted PsA treatments. For PASI outcomes, GUS is considered better than most other targeted PsA treatments.
- Tremfya (guselkumab) / J&J
[VIRTUAL] Guselkumab Improved Work Productivity and Daily Activity in Patients with Psoriatic Arthritis: Results from a Phase 3 Trial () - Oct 8, 2020 - Abstract #ACRARHP2020ACR_ARHP_920;
For PASI outcomes, GUS is considered better than most other targeted PsA treatments. Improvement in overall work productivity and daily activity was greater with GUS versus PBO among patients with moderate-to-severe PsA, resulting in potential annual incremental economic gains
- [VIRTUAL] Comparative Efficacy of Synthetic and Biologic Dmards for Adult Patients with ACTIVE Psoriatic Arthritis in the Russian Federation- A Systematic Review and Network Meta-Analysis () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_1847;
Phase II and III randomised controlled trials (RCTs) evaluating efficacy of sDMARDS (tofacitinib, apremilast) and bDMARDS (netakimab, guselkumab, ustekinumab, secukinumab, ixekizumab, adalimumab, etanercept, infliximab, certolizumab, golimumab) for active PsA were identified by systematic literature review performed in Pubmed and Embase databases. Netakimab is one of the most effective treatments for active PsA.
- Stelara (ustekinumab) / J&J
[VIRTUAL] Efficiency of Innovative Biologics Indicated for Moderate-Severe Psoriasis () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_1632;
Cost analysis per responder (CPR) to achieve PASI100 for IL-17 therapies (brodalumab, secukinumab, ixezikumab), IL-12/23 therapies (ustekinumab), and IL-23 therapies (guselkumab, tildrakizumab, risankizumab) vs. placebo. Brodalumab appears to be a cost-effective alternative versus the current biologic treatments for moderate-severe psoriasis in Spain, being the most cost-efficient alternative within the IL-17 therapeutic group.
- [VIRTUAL] Analysis of the Cost per Responder of Biological Treatments for Moderate to Severe Psoriasis in Argentina () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_1136;
CPR at 2 years (PASI 90; 100): Risankizumab ($2,064,565; $3,611,709), Guselkumab ($2,066,014; $3,836,054), Ixekizumab ($2,494,476; $4,412,817), Secukinumab ($2641,173; $5,335,524), Adalimumab ($2,832,516; $7,357,634), Apremilast ($2,961,656; $14,164,442), Ustekinumab ($3,552,613; $9,159,750), Etanercept ($4,267,464; $17,486,194) and Infliximab ($4,933,087; $10.520.182). CONCLUSIONS : Among the therapies evaluated for moderate to severe psoriasis, Risankizumab, Guselkumab and Ixekizumab shown the highest PASI-90/100 response rates; while Risankizumab would have the lowest CPR PASI-90/100 for all time horizons considered.
- [VIRTUAL] Biologic Treatments for Psoriasis- Cost of Alternative Methods of Dispensation of Medication in Spain () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_683;
Adapting the model of drug dispensation to minimize risk of infections would have economic implications for the NHS. These outcomes would meaningfully vary depending on the site and frequency of dispensation, being the latter dependant on the posology of the biologic treatment.
- Ilumya (tildrakizumab-asmn) / Sun Pharma, Almirall, Tremfya (guselkumab) / J&J
[VIRTUAL] Comparative Efficacy of Guselkumab and Tildrakizumab in Moderate-to-Severe Plaque Psoriasis- A Matching-Adjusted Indirect Comparison () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_505;
Guselkumab also showed better results in PASI 75/100. CONCLUSIONS : Results of this MAIC suggest that PASI response rates are higher for guselkumab compared to tildrakizumab at weeks 12 and 28.
- || Stelara (ustekinumab) / J&J
Clinical, Journal: Therapeutic Targeting of Th17/Tc17 Cells Leads to Clinical Improvement of Lichen Planus. (Pubmed Central) - Oct 1, 2020
These findings show for the first time that therapeutic targeting of Th17/Tc17 cells leads to a pronounced clinical amelioration of mucosal and cutaneous LP and strongly suggests that IL-17-producing T cells are central to disease pathogenesis. Thus, therapeutic targeting of Th17/Tc17 cells opens new therapeutic avenues in the treatment of recalcitrant LP.
- | Tremfya (guselkumab) / J&J
Trial completion date: GALAXI: A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease (clinicaltrials.gov) - Sep 30, 2020
P2/3, N=2000, Recruiting, Sponsor: Janssen Research & Development, LLC
Thus, therapeutic targeting of Th17/Tc17 cells opens new therapeutic avenues in the treatment of recalcitrant LP. Trial completion date: Jul 2028 --> Oct 2024
- | Tremfya (guselkumab) / J&J
Enrollment open: ORCHID-LN: A Study of Guselkumab in Participants With Active Lupus Nephritis (clinicaltrials.gov) - Sep 29, 2020
P2, N=60, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: Jul 2028 --> Oct 2024 Not yet recruiting --> Recruiting
- | Tremfya (guselkumab) / J&J
Trial primary completion date: A Study of Guselkumab in Participants With Familial Adenomatous Polyposis (clinicaltrials.gov) - Sep 19, 2020
P1b, N=72, Recruiting, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2020 --> Jul 2021
- | Tremfya (guselkumab) / J&J
Trial completion date: QUASAR: A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis (clinicaltrials.gov) - Sep 17, 2020
P2b, N=950, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Sep 2020 --> Jul 2021 Trial completion date: Mar 2025 --> Jul 2025
- | Enrollment open, Trial initiation date, Trial primary completion date, Head-to-Head: BeNeBio: Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis (clinicaltrials.gov) - Sep 15, 2020
P4, N=244, Recruiting, Sponsor: Radboud University
Trial completion date: Mar 2025 --> Jul 2025 Not yet recruiting --> Recruiting | Initiation date: May 2020 --> Aug 2020 | Trial primary completion date: Apr 2023 --> Jul 2023
- [VIRTUAL] Novel Monoclonal Antibodies in Late Phase Development for Ulcerative Colitis: A Systematic Review () - Sep 15, 2020 - Abstract #ACG2020ACG_952;
Antibodies directed against IL-23 (mirikizumab), α4β7 and αEβ7 integrins (Etrolizumab), MAdCAM-1 (ontalimumab) were included. The results of clinical response, clinical remission and endoscopic remission are depicted in table 1.
- | Tremfya (guselkumab) / J&J
Journal: Successful use of Guselkumab in the treatment of severe hidradenitis suppurativa. (Pubmed Central) - Sep 13, 2020
Adalimumab and Infliximab are recommended for use in HS Hurley stage 2-3 and there are several reported cases and one case series of successful treatment with Ustekinumab which blocks the p40 subunit of IL-12 and IL-23 . We report a case of successful treatment of HS with a monoclonal antibody (Guselkumab) to the p19 subunit of IL-23.
- Tremfya (guselkumab) / J&J
[VIRTUAL] Real‐world efficacy of guselkumab in the U.K.: 6‐month data from the British Association of Dermatologists’ Biologics and Immunomodulators Register () - Sep 9, 2020 - Abstract #BAD2020BAD_139;
However, this early evidence for guselkumab in a real‐world setting shows strong 6‐month skin clearance responses that are reflective of clinical trial data. The data reported indicate the first real‐world usage of guselkumab in psoriasis in the U.K. and will inform future efficacy and safety analyses.
- Tremfya (guselkumab) / J&J
[VIRTUAL] Real‐world baseline characteristics of U.K. patients treated with guselkumab: the first descriptive analysis from the British Association of Dermatologists’ Biologics and Immunomodulators Register () - Sep 9, 2020 - Abstract #BAD2020BAD_138;
This may indicate the need for an efficacious treatment that improves patient outcomes. The data reported are the first to indicate real‐world usage of guselkumab in psoriasis in the U.K. and will inform future efficacy and safety analyses.
- [VIRTUAL] Phenotypic switch from psoriasis to atopic eczema secondary to biological therapy () - Sep 9, 2020 - Abstract #BAD2020BAD_134;
Implicated biologics included adalimumab (n = 10); etanercept (n = 1); infliximab (n = 1); ixekizumab (n = 2); secukinumab (n = 4); guselkumab (n = 3); and ustekinumab (n = 10)...Treatment strategies for eczema included topical treatment only; oral immunomodulators (ciclosporin, methotrexate or apremilast); or none...Utilizing the British Association of Dermatologists Biologics and Immunomodulators Register is important to document adverse events; the resulting data could allow a more detailed insight into the clinical features and prevalence of atopic eczema secondary to biologics. In‐depth characterization of the genetic basis, cellular and molecular mechanisms of this phenotypic switch is needed to rationalize therapy selection for these patients.
- Tremfya (guselkumab) / J&J
Psoriasis and Crohn's disease secondary to anti IL-17 with good control of digestive symptoms and cutaneous with guselkumab () - Sep 3, 2020 - Abstract #AEDV2020AEDV_175;
- Tremfya (guselkumab) / J&J
Experience in patients with moderate-severe psoriasis treated with guselkumab () - Sep 3, 2020 - Abstract #AEDV2020AEDV_168;
- Tremfya (guselkumab) / J&J
Clinical experience in the use of guselkumab in patients refractory to biological treatment previous: case series from two hospitals () - Sep 3, 2020 - Abstract #AEDV2020AEDV_160;
- Tremfya (guselkumab) / J&J
Pustular psoriasis treated with guselkumab: report of a case () - Sep 3, 2020 - Abstract #AEDV2020AEDV_142;
- Tremfya (guselkumab) / J&J
Effectiveness of guselkumab in routine clinical practice: series of 40 patients in 5 hospitals Andalusian university students () - Sep 3, 2020 - Abstract #AEDV2020AEDV_129;
- Tremfya (guselkumab) / J&J
Guselkumab as a treatment for patients with moderate-severe psoriasis: preliminary results- res after 7 months of experience in clinical practice () - Sep 3, 2020 - Abstract #AEDV2020AEDV_128;
- Tremfya (guselkumab) / J&J, Cosentyx (secukinumab) / Novartis
Consistency of response by disease severity characteristics in patients with moderate to severe psoriasis treated with guselkumab vs secukinumab: week 48 results from ECLIPSE study () - Sep 3, 2020 - Abstract #AEDV2020AEDV_113;